Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor

被引:53
作者
Lepper, ER
Swain, SM
Tan, AR
Figg, WD
Sparreboom, A
机构
[1] NCI, Clin Pharmacol Res Core, Med Oncol Clin Res Unit, Bethesda, MD 20892 USA
[2] NCI, Canc Therapeut Branch, Bethesda, MD 20892 USA
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2003年 / 796卷 / 01期
关键词
pharmacokinetics; erlotinib; OSI-774;
D O I
10.1016/j.jchromb.2003.08.015
中图分类号
Q5 [生物化学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
A high-performance liquid-chromatographic (HPLC) assay with UV detection has been developed for the quantitative determination of erlotinib (OSI-774) in human plasma. Quantitative extraction was achieved by a single-solvent extraction involving a mixture of acetonitrile and n-butyl chloride (1:4, v/v). Erlotinib and the internal standard hydrochloride salt (OSI-597) were separated on a column packed with Nova-Pak C18 material and a mobile phase composed of acetonitrile and water, pH 2.0 (60:40, v/v). The column effluent was monitored with dual UV detection at wavelengths of 348 nm (erlotinib) and 383 mn (OSI-597). The calibration graph was linear in the range of 100-4500 ng/ml, with values for accuracy and precision ranging from 87.9 to 96.2% and 2.13 to 5.10%, respectively, for three different sets of quality control samples. The developed method was successfully applied to study the pharmacokinetics of erlotinib in a cancer patient at the recommended daily dose of 150 mg. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:181 / 188
页数:8
相关论文
共 13 条
[1]
Grunwald Viktor, 2002, Current Problems in Cancer, V26, P109
[2]
Validation of bioanalytical chromatographic methods [J].
Hartmann, C ;
Smeyers-Verbeke, J ;
Massart, DL ;
McDowall, RD .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1998, 17 (02) :193-218
[3]
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies [J].
Hidalgo, M ;
Siu, LL ;
Nemunaitis, J ;
Rizzo, J ;
Hammond, LA ;
Takimoto, C ;
Eckhardt, SG ;
Tolcher, A ;
Britten, CD ;
Denis, L ;
Ferrante, K ;
Von Hoff, DD ;
Silberman, S ;
Rowinsky, EK .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) :3267-3279
[4]
Kim Tracy E, 2002, Curr Opin Investig Drugs, V3, P1385
[5]
Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography [J].
Loos, WJ ;
Verweij, J ;
Nooter, K ;
Stoter, G ;
Sparreboom, A .
JOURNAL OF CHROMATOGRAPHY B, 1997, 693 (02) :437-441
[6]
Ng SSW, 2002, MOL CANCER THER, V1, P777
[7]
Norman P, 2001, Curr Opin Investig Drugs, V2, P298
[8]
Pollack VA, 1999, J PHARMACOL EXP THER, V291, P739
[9]
EPIDERMAL GROWTH FACTOR-RELATED PEPTIDES AND THEIR RECEPTORS IN HUMAN MALIGNANCIES [J].
SALOMON, DS ;
BRANDT, R ;
CIARDIELLO, F ;
NORMANNO, N .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1995, 19 (03) :183-232
[10]
Schillinger JA, 2003, SEX TRANSM DIS, V30, P49, DOI 10.1097/00007435-200301000-00011